What is ICON?
Founded in 1990 and headquartered in Dublin, Ireland, ICON operates as a critical partner for pharmaceutical, biotechnology, and medical device organizations. The company provides comprehensive clinical research, development, and commercialization services that accelerate the path to market for life-saving therapies. By integrating advanced data analytics with deep regulatory expertise, ICON serves as a vital infrastructure provider for the global healthcare industry, ensuring that complex clinical trials and public health initiatives are executed with precision and compliance. Their market position is defined by a robust service portfolio that spans the entire product lifecycle, from early-stage clinical development to post-market commercialization strategies.
How much funding has ICON raised?
ICON has raised a total of $49.1M across 1 funding round:
Stock Offering
$49.1M
Stock Issuance/Offering (1998): $49.1M, investors not publicly disclosed
Key Investors in ICON
ICON
Undisclosed investor participating in the funding round.
What's next for ICON?
With a solid foundation of $49.1M in total capital, ICON is well-positioned to navigate the evolving landscape of global healthcare innovation. The recent strategic investment of $49.1M provides the necessary liquidity to pursue aggressive growth initiatives, including the potential acquisition of niche technology platforms and the expansion of their decentralized clinical trial capabilities. As the industry shifts toward more personalized medicine and digital health integration, ICON's strategic roadmap likely involves deepening its technological moat to maintain its competitive advantage. Investors and stakeholders should anticipate continued focus on operational efficiency and the scaling of global service delivery models to meet the increasing demand for outsourced R&D solutions in an increasingly complex regulatory environment.
See full ICON company page
